CEO total compensation of approximately $23.2 million is elevated relative to typical benchmarks for a $7.5B biotech company, largely because of a $10 million one-time performance stock award granted in December 2025 that requires the stock price to reach between $115 and $170 (an 86–175% increase from grant date) before any shares vest — meaning this award is genuinely at-risk and not guaranteed pay. The overall pay mix is heavily weighted toward variable, long-term equity (regular annual awards consisting of 50% performance stock awards, 35% time-vested stock units, and 15% stock options), which meets the policy's 50–60% variable pay standard, and the company's 3-year TSR of +69.1% is broadly in line with the XBI — SPDR S&P Biotech ETF at +70.0% (a gap of only -0.9 percentage points), demonstrating pay-for-performance alignment. Prior-year say-on-pay support was 96.1%, indicating strong shareholder endorsement of the program structure.

Ernst & Young LLP has served as Halozyme's auditor since June 2006 (approximately 20 years), which is below the 25-year tenure threshold that would trigger a negative vote. Non-audit fees are zero, meaning the non-audit fee ratio is 0% — well within the 50% threshold. No material restatements are disclosed, and EY is a Big 4 firm appropriate for a $7.5B market cap company.